Kurome Therapeutics closes $15 million Series A financing
IMAGE: Jan Rosenbaum is Kurome Chief Executive Officer an Chief Scientific Officer. view more Credit: CincyTech Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing. The round was co-led…
Details